Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
At the meeting, WuXi PharmaTech shareholders approved the re-election ofincumbent Class B directors Xuesong Leng, Zhaohui Zhang, and Ning Zhao, eachto serve a three-year term.
Advertisement
In addition, the WuXi shareholders approved an amendment to the Company'sMemorandum of Articles and Association that revises Article 82 so that it nolonger requires a Special Resolution be obtained for an office of a Directorto be considered vacated.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the United States.As a research-driven and customer-focused company, WuXi PharmaTech provides abroad and integrated portfolio of laboratory and manufacturing servicesthroughout the drug and medical device R&D process. WuXi PharmaTech's servicesare designed to assist its global partners in shortening the cycle andlowering the cost of drug and medical device R&D. WuXi PharmaTech's operatingsubsidiaries are known as WuXi AppTec. For more information, please visit:http://www.wuxiapptec.com .For more information, please contact: WuXi PharmaTech (Cayman) Inc. Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-201-585-2048 Email: [email protected] Stephanie Liu (for the media) WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4362 Email: [email protected]
SOURCE WuXi PharmaTech (Cayman) Inc.
